PA8821301A1 - Inhibidores a base de hidroxamato de desacetilasas b - Google Patents

Inhibidores a base de hidroxamato de desacetilasas b

Info

Publication number
PA8821301A1
PA8821301A1 PA20098821301A PA8821301A PA8821301A1 PA 8821301 A1 PA8821301 A1 PA 8821301A1 PA 20098821301 A PA20098821301 A PA 20098821301A PA 8821301 A PA8821301 A PA 8821301A PA 8821301 A1 PA8821301 A1 PA 8821301A1
Authority
PA
Panama
Prior art keywords
deacetilases
hydroxamate
formula
inhibitors based
present
Prior art date
Application number
PA20098821301A
Other languages
English (en)
Inventor
Shultz Michael
Hiu-Tung Chen Christine
Shin Cho Young
Jiang Lei
Fan Jianmei
Liu Gang
Majumdar Dyuti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8821301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PA8821301A1 publication Critical patent/PA8821301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

LAS ENSEÑANZAS DE LA PRESENTE INVENCIÓN SE REFIEREN A LOS COMPUESTOS DE LA FÓRMULA I: Y SALES, HIDRATOS, ÉSTERES, Y PROFÁRMACOS FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE R1, R2, R3, Y, Z, Y SON TAL COMO SE DEFINE EN LA PRESENTE INVENCIÓN. LAS ENSEÑANZAS DE LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONAN MÉTODOS PARA PREPARAR LOS COMPUESTOS DE LA FÓRMULA I Y MÉTODOS PARA UTILIZAR COMPUESTOS DE LA FÓRMULA I PARA EL TRATAMIENTO, INHIBICIÓN, O PREVENCIÓN DE CONDICIONES O TRASTORNOS PATOLÓGICOS TRANSMITIDOS EN SU TOTALIDAD O EN PARTE POR DESACETILASAS.
PA20098821301A 2008-03-26 2009-03-26 Inhibidores a base de hidroxamato de desacetilasas b PA8821301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3967408P 2008-03-26 2008-03-26

Publications (1)

Publication Number Publication Date
PA8821301A1 true PA8821301A1 (es) 2010-05-26

Family

ID=40591831

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098821301A PA8821301A1 (es) 2008-03-26 2009-03-26 Inhibidores a base de hidroxamato de desacetilasas b

Country Status (33)

Country Link
US (2) US7943652B2 (es)
EP (2) EP2260020B1 (es)
JP (1) JP5330498B2 (es)
KR (1) KR101252349B1 (es)
CN (1) CN102036955B (es)
AR (1) AR071072A1 (es)
AU (1) AU2009228778B2 (es)
BR (1) BRPI0909159A2 (es)
CA (1) CA2719477C (es)
CL (1) CL2009000727A1 (es)
CO (1) CO6531501A2 (es)
CR (1) CR11680A (es)
DO (1) DOP2010000283A (es)
EA (1) EA019033B1 (es)
EC (1) ECSP10010497A (es)
ES (1) ES2519474T3 (es)
GE (1) GEP20125708B (es)
IL (1) IL208212A0 (es)
MA (1) MA32240B1 (es)
MX (1) MX2010010502A (es)
MY (1) MY150437A (es)
NI (1) NI201000157A (es)
NZ (1) NZ588069A (es)
PA (1) PA8821301A1 (es)
PE (1) PE20091736A1 (es)
PL (1) PL2260020T3 (es)
PT (1) PT2260020E (es)
SM (1) SMP201000116B (es)
SV (1) SV2010003677A (es)
TW (1) TWI510467B (es)
UY (1) UY31738A (es)
WO (1) WO2009118305A1 (es)
ZA (1) ZA201006474B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021209A1 (en) * 2009-07-07 2011-02-24 Portsmouth Technologies Llc Histone deacetylase inhibitors
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
WO2013101600A1 (en) * 2011-12-29 2013-07-04 Pharmacyclics, Inc. Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
FR2992317B1 (fr) 2012-06-22 2016-05-13 Diverchim Procede de preparation de peptides chiraux
WO2016025129A1 (en) 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
CN104910074B (zh) * 2015-03-11 2017-07-14 常州大学 一类含有羟肟酸基团的吡唑类衍生物及其制备方法及用途
CR20170420A (es) * 2015-03-13 2017-10-03 Forma Therapeutics Inc Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
CN106854189A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种哌嗪化合物的合成方法
US20170273307A1 (en) * 2016-03-28 2017-09-28 Trent University Silane-based antimicrobial coatings and methods of making and using the same
MX2019009764A (es) 2017-02-17 2019-11-11 Eidos Therapeutics Inc Procesos para preparar acido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
EP3768841A4 (en) 2018-03-23 2021-12-08 Eidos Therapeutics, Inc. METHODS OF TREATING TTR AMYLOSIS USING AG10
BR112020026493A2 (pt) 2018-08-17 2021-03-23 Eidos Therapeutics, Inc. Formulações de ag10
CN113956182B (zh) * 2021-10-11 2023-11-17 杭州师范大学 Hdac/mao-b双重抑制剂及其制备和应用
WO2023114844A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Imidazopyridine psychoplastogens and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
CA2145985C (en) 1992-10-28 2003-09-16 Napoleone Ferrara Vascular endothelial cell growth factor antagonists
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PL190489B1 (pl) 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
CA2264908C (en) 1996-09-06 2006-04-25 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
KR100716272B1 (ko) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
AR035011A1 (es) * 1999-06-30 2004-04-14 Daiichi Seiyaku Co Compuestos inhibidores de vla-4
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002306848A1 (en) * 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP2005517007A (ja) * 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
CN1764648A (zh) * 2003-01-13 2006-04-26 安斯泰来制药有限公司 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
JP2004345953A (ja) 2003-01-16 2004-12-09 Hiroki Koma 抗菌活性を有する新規な第四級アンモニウム塩化合物およびその製造方法
WO2005013958A1 (en) 2003-08-07 2005-02-17 Novartis Ag Histone deacetylase inhibitors as immunosuppressants
EP1653973A1 (en) 2003-08-08 2006-05-10 Novartis AG Combinations comprising staurosporines
WO2007030454A2 (en) 2005-09-07 2007-03-15 Novartis Ag Mutations and polymorphisms of hdac9
WO2007030455A2 (en) 2005-09-07 2007-03-15 Novartis Ag Mutations and polymorphisms of hdac10
US7750155B2 (en) * 2006-02-07 2010-07-06 Astellas Pharma Inc. Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase
US7783564B2 (en) 2006-07-25 2010-08-24 Visa U.S.A. Inc. Compliance control in a card based program
US8093220B2 (en) 2006-12-04 2012-01-10 Novartis Ag Combination of an HDAC inhibitor and an antimetabolite
MX2009012624A (es) 2007-05-30 2009-12-07 Novartis Ag Uso de inhibidores de desacetilasa de histona para el tratamiento de la destruccion osea.

Also Published As

Publication number Publication date
WO2009118305A1 (en) 2009-10-01
ECSP10010497A (es) 2010-10-30
GEP20125708B (en) 2012-12-10
MA32240B1 (fr) 2011-04-01
SMP201000116B (it) 2011-09-09
EP2260020A1 (en) 2010-12-15
PT2260020E (pt) 2014-10-28
AR071072A1 (es) 2010-05-26
DOP2010000283A (es) 2010-10-31
CO6531501A2 (es) 2012-09-28
US8349883B2 (en) 2013-01-08
CA2719477A1 (en) 2009-10-01
BRPI0909159A2 (pt) 2015-11-24
AU2009228778B2 (en) 2012-04-19
CL2009000727A1 (es) 2010-03-26
CN102036955B (zh) 2013-03-27
ES2519474T3 (es) 2014-11-07
AU2009228778A1 (en) 2009-10-01
IL208212A0 (en) 2010-12-30
US20110183964A1 (en) 2011-07-28
ZA201006474B (en) 2011-06-29
EA201001524A1 (ru) 2011-06-30
KR20100125445A (ko) 2010-11-30
EA019033B1 (ru) 2013-12-30
MX2010010502A (es) 2010-10-26
US7943652B2 (en) 2011-05-17
CN102036955A (zh) 2011-04-27
SV2010003677A (es) 2011-07-05
JP2011515437A (ja) 2011-05-19
JP5330498B2 (ja) 2013-10-30
CA2719477C (en) 2016-11-08
EP2260020B1 (en) 2014-07-23
EP2628726A1 (en) 2013-08-21
PL2260020T3 (pl) 2015-01-30
TWI510467B (zh) 2015-12-01
PE20091736A1 (es) 2009-11-19
SMAP201000116A (it) 2011-01-19
NI201000157A (es) 2011-03-29
US20090247547A1 (en) 2009-10-01
NZ588069A (en) 2012-06-29
UY31738A (es) 2009-11-10
TW201004925A (en) 2010-02-01
KR101252349B1 (ko) 2013-04-08
MY150437A (en) 2014-01-30
CR11680A (es) 2010-11-23

Similar Documents

Publication Publication Date Title
PA8821301A1 (es) Inhibidores a base de hidroxamato de desacetilasas b
CO2019001240A2 (es) Inhibidores de cdk2/4/6
PH12015502036A1 (en) Inhibitors of the kynurenine pathway
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
EA201170434A1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
MY172924A (en) Neprilysin inhibitors
ECSP12012103A (es) Inhibidores de virus flaviviridae.
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
ECSP12012104A (es) Inhibidores de virus flaviviridae
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
MX2013010511A (es) Inhibidores triciclicos de girasa.
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
AR085308A1 (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
CU20120085A7 (es) Derivados de sulfamidas heterocíclicas
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
NI201100035A (es) Agentes antifúngicos.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
CO6440577A2 (es) Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona